Background/Aim: The primary role of fine-needle aspiration cytology (FNAC) of salivary gland masses is to determine the underlying process and guide further management. The objective of our study is to provide a comprehensive review of cytologic features and ancillary studies of mammary analog secretory carcinoma (MASC), discuss differential diagnosis and review recent advances in the understanding of its biologic behavior. Case: A 23-year-old female underwent ultrasound-guided FNA of a slowly enlarging parotid mass. Smears displayed branching clusters of bland vacuolated polygonal cells in a secretory proteinaceous background. Eosinophilic cells with eccentric nuclei and inconspicuous nucleoli were also noted. Based on positive intracellular mucin staining and the lack of extracellular-matrix material, the cytologic diagnosis rendered was ‘suspicious for low grade mucoepidermoid carcinoma'. Superficial parotidectomy revealed an MASC confirmed by fluorescence in situ hybridization (FISH) studies for ETV6 translocation. Conclusion: MASC should be included in the differential diagnosis of mucinous salivary lesions with cystic changes on FNA. Immunohistochemistry for mammaglobin and S-100 helps in excluding morphologic mimics. FISH helps to confirm the diagnosis. Age alone should not be a deterrent in diagnosing a carcinoma.

Keywords:
Mammary analog secretory carcinoma, Salivary gland, Fine-needle aspiration, ETV6-NTRK3
1.
Skalova A, Vanecek T, Sima R, et al: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010;34:599-608.
2.
Li Z, Tognon CE, Goginho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim S, Bronson RT, Perou CM, Sorensen PH, Orkin SH: ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 2007;12:542-558.
3.
Pisharodi L: Mammary analog secretory carcinoma of salivary gland: cytologic diagnosis and differential diagnosis of an unreported entity. Diagn Cytopathol 2013;41:239-241.
4.
Bishop JA, Yonescu R, Batista DA, Westra WH, Ali SZ: Cytopathologic features of mammary analogue secretory carcinoma. Cancer Cytopathol 2013;121:228-233.
5.
Griffith CC, Stelow EB, Saqi A, et al: The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases. Cancer Cytopathol 2013;121:234-241.
6.
Levine P, Fried K, Krevitt LD, Wang B, Wenig BM: Aspiration biopsy of mammary analogue secretory carcinoma of accessory parotid gland: another diagnostic dilemma in matrix-containing tumors of the salivary glands. Diagn Cytopathol 2014;42:49-53.
7.
Sethi R, Kozin E, Remenschneider A, et al: Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope 2014;124:188-195.
8.
Petersson F, Lian D, Chau YP, Yan B: Mammary analogue secretory carcinoma: the first submandibular case reported including findings on fine needle aspiration cytology. Head Neck Pathol 2012;6:135-139.
9.
Chiosea SI, Griffith C, Assaad A, Seethala RR: Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology 2012;61:387-394.
10.
Jung MJ, Song JS, Kim SY, et al: Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol 2013;47:36-43.
11.
Skalova A, Vanecek T, Majewska H, et al: Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, [beta]-catenin, EGFR, and CCND1 genes. Am J Surg Pathol 2014;38:23-33.
12.
Higuchi K, Urano M, Takahashi RH, Oshiro H, Matsubayashi J, Nagai T, Obikane H, Shimojo H, Nagao T: Cytological features of mammary analogue secretory carcinoma of salivary gland: fine-needle aspiration of seven cases. Diagn Cytopathol 2014;42:846-855.
13.
Takeda M, Kasai T, Morita K, Takeuchi M, Nishikawa T, Yamashita A, Mikami S, Hosoi H, Ohbayashi C: Cytological features of mammary analogue secretory carcinoma - review of literature. Diagn Cytopathol 2014, Epub ahead of print.
14.
Gnepp DR: Salivary gland tumor ‘wishes' to add to the next WHO tumor classification: sclerosing polycystic adenosis, mammary analogue secretory carcinoma, cribriform adenocarcinoma of the tongue and other sites, and mucinous variant of myoepithelioma. Head Neck Pathol 2014;8:42-49.
15.
Krane JF, Faquin WC, Salivary gland; in Cibas ES, Ducatman BS (eds): Cytology: Diagnostic Principles and Clinical Correlates. New York, WB Saunders, 2003, pp 273-306.
16.
Patel KR, Solomon IH, El-Mofty SK, Lewis JS, Chernock RD: Mammaglobin and S-100 immunoreactivity in salivary gland carcinomas other than mammary analogue secretory carcinoma. Hum Pathol 2013;44:2501-2508.
17.
Mariano FV, Tavares dos Santos H, Azanero WD, Werneck da Cunha I, Coutinho-Camilo CM, Paes de Almeida O, Kowalski L, Altermani A: Mammary analogue secretory carcinoma of salivary glands is a lipid-rich tumour, and adipophilin can be valuable in its identification. Histopathology 2013;63:558-567.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.